Mark Mitton-Fry

Mark Mitton-Fry

Mark Mitton-Fry, PhD

Assistant Professor
Medicinal Chemistry and Pharmacognosy
338 Parks Hall
mitton-fry.1@osu.edu
(614) 292-1903

Journal Articles

  • Lall, M. S.; Tao, Y.; Arcari, J. T.; Boyles, D.; Brown, M. F.; Damon, D. B.; Lilley, S. C.; Mitton-Fry, M. J.; Starr, J. T.; Stewart, A. M.; Sun, J. Process Development for the Synthesis of Monocyclic -Lactam Core 17. Org. Process Res. Dev. 2018, 22, 212-218, DOI: 10.1021/acs.oprd.7b00359.
  • Vazquez, M. L.; Kaila, N.; Strohbach, J. W.; Trzupek, J. D.; Brown, M. F.; Flanagan, M. E.; Mitton-Fry, M. J.; Johnson, T. A.; TenBrink, R. E.; Arnold, E. P.; Basak, A.; Heasley, S. E.; Kwon, S.; Langille, J.; Parikh, M. D.; Griffin, S. H.; Casavant, J. M.; Duclos, B. A.; Fenwick, A. E.; Harris, T. M.; Han, S.; Caspers, N.; Dowty, M. E.; Yang, X.; Banker, M. E.; Hegen, M.; Symanowicz, P. T.; Li, L.; Wang, L.; Lin, T. H.; Jussif, J.; Clark, J. D.; Telliez, J.-B.; Robinson, R. P.; Unwalla, R.; Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. J. Med. Chem. 2018, 61, 1130-1152, DOI: 10.1021/acs.jmedchem.7b01598.
  • Linsen Li, Antony A. Okumu, Sheri Nolan, Anthony English, Sandip Vibhute, Yanran Lu, Katherine Hervert-Thomas, Justin T. Seffernick, Lovette Azap, Serena L. Cole, D. Shinabarger, Laura M. Koeth, Steffen Lindert , Jack C. Yalowich, Daniel J. Wozniak, and Mark J. Mitton-Fry1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition ACS Infect. Dis. 2019 DOI: 10.1021/acsinfecdis.8b00375.
  • M. J. Mitton-Fry, S. J. Brickner, J. C. Hamel, R. Barham, L. Brennan, J.M. Casavant, X. Ding, S. Finegan, J. Hardink, T. Hoang, M.D. Huband, M. Maloney, A. Marfat, S.P. McCurdy, D. McLeod, C. Subramanyam, M. Plotkin, U. Reilly, J. Schafer, G.G. Stone, D.P. Uccello, T. Wisialowski, K. Yoon, R. Zaniewski, C. ZookNovel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV Bioorg. Med. Chem. Lett., 27:3353-3358, DOI: 10.1016/j.bmcl.2017.06.009.
  • Mitton-Fry, M. J.Novel bacterial type II topoisomerase inhibitors In Medicinal Chemistry Reviews, Vol. 52, Bronson, J., Ed.; American Chemical Society, 2017, pp. 281-302.
  • Li, L.; Okumu, A.; Dellos-Nolan, S.; Li, Z.; Karmahapatra, S.; English, A.; Yalowich, J. C.; Wozniak, D. J.; Mitton-Fry, M. J. Synthesis and Anti-staphylococcal activity of Novel Bacterial Topoisomerase Inhibitors with a 5-amino-1,3-dioxane Linker Moiety Bioorg. Med. Chem. Lett. 2018, 28, 2477-2480. DOI: 10.1016/j.bmcl.2018.06.003.